SCHEMBL3606924

SCHEMBL3606924

NC1CCN(CCN2c3ccccc3N(c3ccccc3F)S2(O)O)CC1

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 11/20 0.37
SLC6A3 Q01959 5/20 0.37
SLC6A4 P31645 4/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
HTR1A P08908 1/20 0.34
HTR7 P34969 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3611857 0.99 SLC6A2 (0.36) SLC6A2SLC6A3SLC6A4KDM4EALDH1A1
SCHEMBL3606091 0.93 SLC6A2 (0.40) SLC6A2SLC6A3SLC6A4HTR1AHTR7
Hydrochloric Acid SCHEMBL3606848 0.92 SLC6A2 (0.40) SLC6A2SLC6A3SLC6A4HTR1AHTR7
SCHEMBL3606921 0.85 SLC6A2 (0.53) SLC6A2SLC6A3SLC6A4
SCHEMBL3603035 0.85 SLC6A2 (0.38) SLC6A2SLC6A3SLC6A4
SCHEMBL3612639 0.85 SLC6A2 (0.42) SLC6A2SLC6A3SLC6A4ALDH1A1
Hydrochloric Acid SCHEMBL3611851 0.84 SLC6A2 (0.52) SLC6A2SLC6A3SLC6A4
Hydrochloric Acid SCHEMBL3603335 0.84 SLC6A2 (0.38) SLC6A2SLC6A3SLC6A4
Hydrochloric Acid SCHEMBL3605276 0.84 SLC6A2 (0.41) SLC6A2SLC6A3SLC6A4ALDH1A1
Hydrochloric Acid SCHEMBL3616431 0.79 SLC6A2 (0.34) SLC6A2SLC6A3SLC6A4KDM4EHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2010-02-04 US claimed
US-7601722-B2 Aryl sulfamide derivatives and methods of their use WYETH (US) 2009-10-13 US claimed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP claimed
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-10 US claimed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO claimed
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2010-02-04 US disclosed
US-7601722-B2 Aryl sulfamide derivatives and methods of their use WYETH (US) 2009-10-13 US disclosed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-10 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885SLC6A3 3/4885SLC6A4 1/4885
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885SLC6A3 3/4885SLC6A4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.